Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 12, 2016, Pages 2342-2352

  Teng, R ^a   Carlson, G F ^a   Nylander, S ^b   Andersson, T L G ^b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

antiplatelet agents; clopidogrel; platelet aggregation; platelet transfusion; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; ALLELE; ARTICLE; BLOOD AUTOTRANSFUSION; BODY MASS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; PETECHIA; PLATELET INHIBITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; ANALOGS AND DERIVATIVES; APHERESIS; CASE CONTROL STUDY; CYTOLOGY; DRUG EFFECTS; GENETICS; PROCEDURES; REPRODUCIBILITY; THROMBOCYTE; TIME FACTOR; YOUNG ADULT;

ADENOSINE; ADULT; BLOOD COMPONENT REMOVAL; BLOOD PLATELETS; BODY MASS INDEX; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2C19; FEMALE; HEMOSTASIS; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET TRANSFUSION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; REPRODUCIBILITY OF RESULTS; TICLOPIDINE; TIME FACTORS; YOUNG ADULT;

EID: 84996847812     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13511     Document Type: Article

References (46)

1. Husted S, van Giezen JJJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009; 27: 259–74.
2. van Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasely PJ. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and PA. J Thromb Haemost 2009; 7: 1556–65.
3. Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther 2014; 19: 209–19.
4. Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 2014; 63: 2503–9.
5. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010; 66: 487–96.
6. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010; 70: 65–77.
7. Fareed J, Jeske W, Thethi I. Metabolic differences of current thienopyridine antiplatelet agents. Expert Opin Drug Metab Toxicol 2013; 9: 307–17.
8. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010; 38: 1514–21.
9. Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug–drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction and differential kinetics. Drug Metab Dispos 2011; 39: 703–10.
10. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, for the PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57.
11. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsoon O, Oude Ophis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, et al, for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791–800.
12. Alfredsson J, Roe MT. Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. J Am Heart Assoc 2015; 4: e001897.
13. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby K, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362–425.
14. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130: e344–426.
15. Nácul FE, de Moraes E, Penido C, Paiva RB, Méier-Neto JG. Massive nasal bleeding and hemodynamic instability associated with clopidogrel. Pharm World Sci 2004; 26: 6–7.
16. Leithäuser B, Zielske D, Seyfert UT, Jung F. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc 2008; 39: 293–302.
17. Levine M, Swenson S, McCormick T, Henderson SO, Thomas SH, Markland FS. Reversal of thienopyridine-induced platelet dysfunction following desmopressin administration. J Med Toxicol 2013; 9: 139–43.
18. Teng R, Mitchell P, Butler K. The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. J Clin Pharm Ther 2014; 39: 186–91.
19. Kauffman RM, Djulbegovia B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, Cipolle MD, Cohn CS, Fung MK, Grossman BJ, Mintz PD, O'Malley BA, Sesok-Pizzini DA, Shander A, Stack GE, Webert KE, Weinstein R, Welch BG, Whitman GJ, Wong EC, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015; 162: 205–13.
20. Ferraris VA, Saha SP, Oestreich JH, Song HK, Rosengart T, Reece TB, Mazer CD, Bridges CR, Despotis GJ, Jointer K, Clough ER. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg 2012; 194: 1761–81.
21. Capodanno D, Angiolillo DJ. Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. Circulation 2013; 128: 2785–98.
22. Vilahur G, Choi BG, Zfar MU, Viles-Gonzalex JF, Vorchheimer DA, Fuster V, Badimon JJ. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost 2007; 5: 82–90.
23. Hansson EC, Shams Hakimi C, Åström-Olsson K, Hesse C, Wallén H, Delborq M, Albertsson P, Jeppsson A. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth 2014; 112: 570–5.
24. Scharbert G, Wetzel L, Schrottmaier WC, Kral JB, Weber T, Assinger A. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets. Transfusion 2015; 55: 1320–6.
25. Li C, Hirsh J, Xie C, Johnston MA, Eikelboom JW. Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost 2012; 10: 521–8.
26. O'Connor SA, Amour J, Mercadier A, Martin R, Kerneis M, Abtan J, Brugier D, Silvain J, Barthélémy O, Leprince P, Montalescot G, Collet JP, ACTION Study Group. Efficacy of ex vivo and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. Circ Cardiovasc Interv 2015; 8: e002786.
27. Bonhome F, Bonvini R, Reny JL, Poncet A, Fontana P. Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: an ex vivo study. Platelets 2015; 26: 324–30.
28. Zafar MU, Santos-Gallego C, Vorchheimer DA, Viles-Gonzalez JF, Elmariah S, Giannarellis C, Sartori S, Small DS, Jakubowski JA, Fuster V, Badimon JJ. Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. J Thromb Haemost 2013; 11: 100–6.
29. Prüller F, Drexler C, Archan S, Macher S, Raggam RB, Mahla E. Low platelet reactivity is recovered by transfusion of stored platelets: a healthy volunteer in vivo study. J Thromb Haemost 2011; 9: 1670–3.
30. Martin A-C, Berndt C, Calmette L, Philip I, Decouture B, Gaussem P, Gouin-Thibault I, Samama C-M, Bachelot-Loza C, Godier A. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in vitro study. Eur J Anaesthesiol 2015; 32: 1–7.
31. Hobl EL, Derhaschnig U, Firbas C, Schoergenhofer C, Schwameis M, Jilma B. Reversal strategy in antagonizing the P2Y12-inhibitor ticagrelor. Eur J Clin Invest 2013; 43: 1258–61.
32. Schoener L, Richter B, Pfluecke C, Christoph M, Quick S, Poitz D, Strasser RH, Ibrahim K. A new strategy to reverse the platelet inhibitory effect of ticagrelor. Eur Heart J 2015; 36(Abstract Supplement): 860.
33. Dalén M, Ivert T, Lindvall G, van der Linden J. Ticagrelor-associated bleeding in a patient undergoing surgery for acute type A aortic dissection. J Cardiothorac Vasc Anesth 2013; 27: e55–7.
34. Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med 2015; 372: 196–7.
35. Maillard J, Cartier Faessler V, Fontana P, Bonhomme F. Lack of effect of platelet transfusions and desmopressin on intracranial bleeding in a patient receiving ticagrelor. A A Case Rep 2015; 4: 169–71.
36. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927–9.
37. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188–99.
38. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patel SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577–85.
39. Teng R, Butler K. Lack of clinically significant pharmacological interactions between ticagrelor and enoxaparin or unfractionated heparin in healthy subjects. J Clin Pharm Ther 2012; 37: 704–11.
40. Thiele T, Sümnig A, Hron G, Müller C, Althaus K, Schroeder HWS, Greinacher A. Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study. J Thromb Haemost 2012; 10: 968–71.
41. Eli Lilly and Company. Effient (prasugrel) tablets. Approved prescribing information. Updated July 2015. Available at: http://pi.lilly.com/us/effient.pdf. Accessed 28 November 2015.
42. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, et al.; Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267–315.
43. Sillén H, Cook M, Davis P. Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 2315–22.
44. Pehrsson S, Hansson K, Nelander K, Nylander S. Boosting the coagulation restores homeostasis in ticagrelor-treated mice. Blood Coagul Fibrinolysis 2016. epub ahead of print.
45. Buchanan A, Newton P, Pehrsson S, Inghardt T, Antonsson T, Svensson P, Sjögren T, Öster L, Janefeldt A, Sandinge AS, Keyes F, Austin M, Spooner J, Gennemark P, Penney M, Howells G, Vaughan T, Nylander S. Structural and functional characterisation of a specific antidote for ticagrelor. Blood 2015; 125: 3484–90.
46. Bakry B, Sayed D, Galal H, Shaker S. Platelet function, activation and apoptosis during and after apheresis. Ther Apher Dial 2010; 14: 457–64.